When Does the Patent for BioCryst's Orladeyo Expire?
The primary patents protecting BioCryst's Orladeyo (berotralstat) are set to expire around 2026. Specifically, U.S. Patent No. 10,596,403, which covers the method of treating hereditary angioedema (HAE) with berotralstat, is listed with an expiry date in 2026 [1].
Are There Patent Lawsuits Involving Orladeyo?
Information regarding ongoing or recent patent lawsuits specifically for BioCryst's Orladeyo in 2026 is not publicly detailed in the provided information. However, patent challenges are common for branded pharmaceuticals as their exclusivity periods approach expiration, often involving Paragraph IV certifications under the Hatch-Waxman Act. These challenges can lead to litigation where generic manufacturers seek to market their versions of the drug before the listed patent expiry dates [2].
What Does Patent Expiry Mean for Orladeyo?
Once the core patents for Orladeyo expire, it opens the door for other companies to potentially develop and seek approval for generic versions of the drug. This could lead to increased competition and, typically, a reduction in the drug's price for patients and healthcare systems. The timeline for generic entry can be influenced by further patent litigation and the outcome of any challenges.
How Does Orladeyo Work for Hereditary Angioedema?
Orladeyo is a plasma kallikrein inhibitor. By blocking the activity of plasma kallikrein, it prevents the overproduction of bradykinin, a substance that causes the swelling attacks characteristic of HAE. It is taken orally once daily [1].